Skip to main content
Sequana Medical N.V. logo

Sequana Medical N.V. — Investor Relations & Filings

Ticker · SEQUA ISIN · BE0974340722 LEI · 8755009AN12Y4PEOII07 BR Manufacturing
Open in API
Filings indexed 501 across all filing types
Latest filing 2025-06-06 Share Issue/Capital Cha…
Country BE Belgium
Listing BR SEQUA

About Sequana Medical N.V.

https://www.sequanamedical.com/

Sequana Medical N.V. is a commercial-stage medical device company focused on developing treatments for drug-resistant fluid overload, a frequent complication in patients with liver disease, heart failure, and cancer. The company's primary product is the alfapump®, a fully implanted, wirelessly charged system that automatically and continuously removes ascites (fluid accumulation in the abdomen) into the bladder for natural elimination. It is the first U.S. FDA-approved active implantable medical device for treating recurrent or refractory ascites due to liver cirrhosis, designed to reduce or eliminate the need for therapeutic paracentesis. Sequana Medical is also advancing its DSR® (Direct Sodium Removal) therapy platform, a novel approach for managing fluid overload in heart failure patients.

Recent filings

Filing Released Lang Actions
1 -- Sequana Medical - Press Release Capital Increase (NL) (6 June 2025).pdf
Share Issue/Capital Change Classification · 99% confidence The document is titled with a date and explicitly marked as 'PERSBERICHT GEREGLEMENTEERDE INFORMATIE' (Regulated Information Press Release). The content details a significant change in the company's capital structure: an increase in capital and the issuance of new shares (2,538,501 new shares) to GEM under a pre-existing share subscription facility agreement. This announcement directly relates to changes in the company's share count and capital base, which falls under financing activities or capital structure changes. This aligns best with the 'Capital/Financing Update' category (CAP). It is not a full Annual Report (10-K), an Earnings Release (ER), or a Dividend Notice (DIV). Since it is a specific announcement about capital changes, CAP is more precise than the general 'Regulatory Filings' (RNS).
2025-06-06 Dutch
Sequana Medical - GRAC Transparency Notification PR (ENG) - (6 June 2025).pdf
Declaration of Voting Results & Voting Rights Announcements Classification · 100% confidence The document is titled 'Transparency Notification from Shareholders' and details the receipt of a notification regarding a change in major shareholding (GRAC société simple crossing the 5% threshold). It explicitly references compliance with Article 14 of the Belgian Act on the disclosure of major participations. This content directly corresponds to notifications about changes in significant share ownership, which aligns with the definition for Major Shareholding Notification (MRQ). Although it is a press release announcing the notification, the core subject matter is the change in major shareholding, making MRQ the most specific classification over a general Regulatory Filing (RNS) or Report Publication Announcement (RPA).
2025-06-06 English
Sequana Medical - GRAC Transparency Notification PR (NL) - (6 June 2025).pdf
Major Shareholding Notification Classification · 99% confidence The document is titled "Transparantiekennisgeving van Aandeelhouders" (Shareholder Transparency Notification) and details the receipt of notification regarding a change in shareholding percentage (5.12%) by an entity named GRAC société simple. It explicitly mentions the crossing of the 5% threshold as required by Belgian law (Article 14 of the law of May 2, 2007) concerning the disclosure of major shareholdings. This directly corresponds to the definition of a Major Shareholding Notification (MRQ), which covers notifications of changes in significant share ownership levels crossing thresholds.
2025-06-06 Dutch
250526 Press release_FPIM CLA investment (ENG).pdf
Earnings Release Classification · 95% confidence The document is explicitly titled and formatted as a "PRESS RELEASE REGULATED INFORMATION – INSIDE INFORMATION". It announces a specific corporate action: securing additional convertible financing (EUR 6.3 Million) and updates on the cash runway and US commercial launch timeline for their product, alfapump. This type of announcement, detailing financing, operational updates, and market strategy, is characteristic of an Earnings Release (ER) or a general Regulatory Filing (RNS). Since it provides key financial updates (financing secured, cash runway extended) but is not the full, comprehensive quarterly/annual report (like 10-K or IR), and it is a formal press release, the most appropriate classification is Earnings Release (ER), as it communicates recent financial performance context and outlook. It is not a Call Transcript (CT), Investor Presentation (IP), or a formal Audit Report (AR). Given the focus on financing and operational milestones, ER is the best fit among the specific options, although RNS is a close secondary fallback. FY 2024
2025-05-27 English
250526 Press release_FPIM CLA investment (NL).pdf
Earnings Release Classification · 92% confidence The document is explicitly titled "PERSBERICHT GEREGLEMENTEERDE INFORMATIE – VOORWETENSCHAP" (Regulated Information Press Release - For Information Only) and is dated May 27, 2025. The content details a significant financing event (obtaining EUR 6.3 million in convertible financing) and provides updates on commercial launch timelines and clinical progress. This structure—a formal announcement of material, non-public information intended for immediate dissemination to the market—is characteristic of an Earnings Release (ER) or a general Regulatory Filing (RNS). Since it focuses on financial updates (new capital, cash runway extension) and operational milestones (US launch schedule), it aligns closely with the purpose of an Earnings Release (ER), which announces key financial results and operational highlights for a period, even if it's not a standard quarterly earnings report. Given the focus on capital structure changes and operational progress following prior announcements, it functions as a material update. It is not a full Annual Report (10-K), a transcript (CT), or a proxy statement (DEF 14A). While it could be RNS as a fallback, the specific nature of the financial/operational update makes ER a better fit, as it communicates key performance indicators and financial positioning. However, since it is primarily about securing financing and operational updates rather than reporting comprehensive periodic financial results (like revenue/net income), and it is explicitly labeled as a 'Press Release' announcing regulated information, the most appropriate general category for a material, non-standard announcement is often RNS, or ER if it contains key financial metrics. Given the strong emphasis on securing capital and extending runway, it is a significant financial event announcement. I will classify it as an Earnings Release (ER) because it updates the market on financial health and operational progress, which is a core function of ERs, even outside of standard quarterly reporting cycles. If it were purely about the mechanics of the financing without operational context, CAP might apply, but the breadth suggests ER or RNS. ER is chosen due to the financial nature of the primary news. Q2 2025
2025-05-27 Dutch
20250522 Sequana Medical - Press release Results AGM EGM (ENG).pdf
AGM Information Classification · 98% confidence The document is explicitly titled "Sequana Medical announces results of Annual and Extraordinary General Meetings of Shareholders." It details that all proposed resolutions submitted to the Annual and Extraordinary General Meetings (AGM/EGM) were approved, including resolutions related to financial years, director reappointments, and share issuances. This content directly relates to the outcomes and proceedings of a shareholder meeting, matching the definition for AGM Information (AGM-R). Although it mentions the approval of the remuneration report (related to DEF 14A), the primary focus and context is the meeting results themselves.
2025-05-22 English

Browse filings by year

8 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.